Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Molecular basis of antifungal drug resistance in yeasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in Pseudomonas aeruginosa in a Murine Biofilm Wound Model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: Not just hot air

    Research output: Contribution to journalReviewpeer-review

View graph of relations

Cystic fibrosis (CF) patients are at risk of acquiring chronic Pseudomonas aeruginosa lung infections. The biofilm mode of growth of P. aeruginosa induces tolerance to antibiotics and the host response; accordingly, treatment failure occurs. Supplemental azithromycin has proven beneficial in CF owing to potential immunomodulatory mechanisms. Clinical studies have demonstrated a reduction in exacerbations in CF patients by avian IgY anti-Pseudomonas immunotherapy. We hypothesise that azithromycin pre-treatment could potentiate the observed anti-Pseudomonas effect of IgY opsonisation in vivo. Evaluation of phagocytic cell capacity was performed using in vitro exposure of azithromycin pre-treated human polymorphonuclear neutrophils to IgY opsonised P. aeruginosa PAO3. A murine lung infection model using nasal planktonic P. aeruginosa inoculation and successive evaluation 24 h post-infection was used to determine lung bacteriology and subsequent pulmonary inflammation. Combined azithromycin treatment and IgY opsonisation significantly increased bacterial killing compared with the two single-treated groups and controls. In vivo, significantly increased bacterial pulmonary elimination was revealed by combining azithromycin and IgY. A reduction in the inflammatory markers mobiliser granulocyte colony-stimulating factor (G-CSF), macrophage inflammatory protein 2 (MIP-2) and interleukin 1 beta (IL-1β) paralleled this effect. Combination of azithromycin and anti-Pseudomonas IgY potentiated the killing and pulmonary elimination of P. aeruginosa in vitro and in vivo. The augmented effect of combinatory treatment with azithromycin and IgY constitutes a potential clinical application for improving anti-Pseudomonas strategies.

Original languageEnglish
Article number106213
JournalInternational Journal of Antimicrobial Agents
Volume57
Issue number1
Pages (from-to)106213
ISSN0924-8579
DOIs
Publication statusPublished - 1 Jan 2021

    Research areas

  • Avian IgY, Azithromycin, Cystic fibrosis, In vivo, Pseudomonas aeruginosa

ID: 61371758